Valuation: Exelixis, Inc.

Market Cap 1.44TCr 1.26TCr 1.19TCr 1.09TCr 2.04TCr 1,38100Cr 2.05TCr 14TCr 5.54TCr 71TCr 5.41TCr 5.29TCr 2,26800Cr P/E 2026 *
18x
P/E 2027 * 14.9x
Enterprise Value 1.37TCr 1.2TCr 1.13TCr 1.03TCr 1.93TCr 1,31000Cr 1.95TCr 14TCr 5.25TCr 67TCr 5.13TCr 5.02TCr 2,15100Cr EV / Sales 2026 *
5.35x
EV / Sales 2027 * 4.41x
Free-Float
98.15%
Yield 2026 *
-
Yield 2027 * -
1 day+0.36%
1 week-0.34%
Current month+6.44%
1 month+2.54%
3 months+9.26%
6 months+35.94%
Current year+32.69%
1 week 56.26
Extreme 56.26
59.09
1 month 53.43
Extreme 53.4283
59.72
Current year 39.71
Extreme 39.71
59.72
1 year 33.76
Extreme 33.755
59.72
3 years 18.64
Extreme 18.64
59.72
5 years 14.87
Extreme 14.87
59.72
10 years 10.04
Extreme 10.04
59.72
Manager TitleAgeSince
Chief Executive Officer 65 22/07/2010
Director of Finance/CFO 58 15/07/2015
Chief Operating Officer 63 01/02/2016
Director TitleAgeSince
Director/Board Member 70 01/02/2004
Director/Board Member 82 01/08/2004
Chairman 77 01/01/1998
Date Insider Type Main position Quantity % Market Cap. Importance
10/08/26 Sell

Director

-9,812 0.0039%
01/06/26 Sell

Director

-9,812 0.0039%
01/06/26 Sell

Director

-3,925 0.0016%
Change 5-day change 1-year change 3-year change Capi.($)
+0.36%-0.34%+50.32%+166.42% 1.44TCr
-3.30%+1.50%+51.24%+99.26% 7.23TCr
+1.25%-3.01%+40.12%+77.12% 6.02TCr
+2.12%+5.26%+32.50%+21.28% 2.77TCr
-3.06%-1.81%-13.10%+357.06% 2.57TCr
-0.75%+2.56%+0.45%-4.46% 2.47TCr
+0.40%+0.75%+22.91%-9.68% 2.07TCr
-1.70%-2.12%+146.86%+314.52% 1.51TCr
+0.21%+1.17%-8.07%+499.10% 1.42TCr
-4.70%-12.55%-22.95%+713.02% 1.25TCr
Average -0.92%-0.86%+30.03%+223.36% 2.88TCr
Weighted average by Cap. -0.94%-0.25%+33.75%+154.39%

Financials

2026 *2027 *
Net sales 255.26Cr 223.99Cr 211.55Cr 192.79Cr 360.89Cr 24TCr 363.47Cr 2.53TCr 980.51Cr 12TCr 958.41Cr 937.68Cr 40TCr 289.99Cr 254.46Cr 240.33Cr 219.02Cr 409.99Cr 28TCr 412.91Cr 2.88TCr 1.11TCr 14TCr 1.09TCr 1.07TCr 46TCr
Net income 82Cr 72Cr 68Cr 62Cr 116.03Cr 7.87TCr 116.85Cr 813.88Cr 315.23Cr 4.02TCr 308.12Cr 301.46Cr 13TCr 101.23Cr 89Cr 84Cr 76Cr 143.13Cr 9.7TCr 144.15Cr 1TCr 388.86Cr 4.96TCr 380.09Cr 371.87Cr 16TCr
Net Debt -74Cr -65Cr -62Cr -56Cr -105.25Cr -7.14TCr -106.01Cr -738.33Cr -285.97Cr -3.65TCr -279.52Cr -273.48Cr -12TCr -162.27Cr -142.39Cr -134.48Cr -122.55Cr -229.41Cr -16TCr -231.05Cr -1.61TCr -623.3Cr -7.95TCr -609.25Cr -596.07Cr -26TCr
Logo Exelixis, Inc.
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Employees
1,077
Date Price Change Volume
25/26/25 $58.16 +0.36% 19,89,681
24/26/24 $57.95 +2.15% 19,25,760
23/26/23 $56.73 -2.44% 14,31,534
22/26/22 $58.15 +1.63% 18,60,283
21/26/21 $57.22 -1.95% 21,02,596
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
58.16USD
Average target price
53.69USD
Spread / Average Target
-7.69%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EXEL Stock